Stock 301047 SINO BIOLOGICAL,INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Sino Biological,Inc.

Equities

301047

CNE100004Q23

Biotechnology & Medical Research

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-05-06 pm EDT 		5-day change 1st Jan Change
74.24 CNY +2.56% Intraday chart for Sino Biological,Inc. +5.29% -9.90%
Apr. 28 Sino Biological,Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 26 Sino Biological,Inc. completed the acquisition of SignalChem Biotech Inc. from Signalchem Lifesciences Corporation. CI

Valuation

Fiscal Period: December 2021 2022 2023 2024 2025
Capitalization 1 23,508 12,876 10,646 9,485 -
Enterprise Value (EV) 1 23,508 12,876 10,646 9,485 9,485
P/E ratio 27.2 x 37.4 x 40.9 x 29 x 25.3 x
Yield 2.89% 2.01% 2.43% 1.9% -
Capitalization / Revenue 24.4 x 22.4 x 16.5 x 13.2 x 11.6 x
EV / Revenue 24.4 x 22.4 x 16.5 x 13.2 x 11.6 x
EV / EBITDA 27.2 x 35.7 x 31 x 25.3 x 23 x
EV / FCF 39,527,345 x - - - -
FCF Yield 0% - - - -
Price to Book 3.48 x 2.02 x 1.67 x 1.46 x 1.42 x
Nbr of stocks (in thousands) 129,200 129,200 129,200 127,760 -
Reference price 2 181.9 99.66 82.40 74.24 74.24
Announcement Date 2/27/22 4/21/23 4/23/24 - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2021 2022 2023 2024 2025
Net sales 1 965.3 574.6 646.4 720.5 819
EBITDA 1 864.2 360.7 342.9 375 413
EBIT 1 841.7 342.5 287.9 379.5 407
Operating Margin 87.2% 59.61% 44.55% 52.67% 49.69%
Earnings before Tax (EBT) 1 845.5 342.5 287.9 380.5 408
Net income 1 720 303.1 260.1 331 378.4
Net margin 74.59% 52.76% 40.24% 45.94% 46.2%
EPS 2 6.687 2.661 2.013 2.557 2.930
Free Cash Flow 594.7 - - - -
FCF margin 61.61% - - - -
FCF Conversion (EBITDA) 68.82% - - - -
FCF Conversion (Net income) 82.6% - - - -
Dividend per Share 2 5.263 2.000 2.000 1.410 -
Announcement Date 2/27/22 4/21/23 4/23/24 - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2021 2022 2023 2024 2025
Net Debt - - - - -
Net Cash position - - - - -
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow 595 - - - -
ROE (net income / shareholders' equity) 18.8% 4.74% 4.11% 5.05% 5.53%
ROA (Net income/ Total Assets) - - - 5% 5.1%
Assets 1 - - - 6,620 7,420
Book Value Per Share 2 52.30 49.30 49.30 51.00 52.40
Cash Flow per Share 2 5.970 1.930 2.500 2.740 -
Capex 1 47.9 156 1,043 94 81
Capex / Sales 4.96% 27.16% 161.41% 13.05% 9.89%
Announcement Date 2/27/22 4/21/23 4/23/24 - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Sino Biological,Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
74.24 CNY
Average target price
102.5 CNY
Spread / Average Target
+38.07%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
SINO BIOLOGICAL,INC. Stock Sino Biological,Inc.
-9.90% 1.31B
MODERNA, INC. Stock Moderna, Inc.
+21.74% 46.4B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-0.97% 41.75B
LONZA GROUP AG Stock Lonza Group AG
+49.51% 41.37B
CELLTRION, INC. Stock Celltrion, Inc.
-3.52% 29.71B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.12% 26.01B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-19.37% 19.52B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+31.18% 12.43B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-0.04% 12.13B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.39% 12.18B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. 301047 Stock
  4. Financials Sino Biological,Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW